Brief Visuospatial Memory Test-Revised: normative data and clinical utility of learning indices in Parkinson’s disease

2020 ◽  
Vol 42 (10) ◽  
pp. 1099-1110
Author(s):  
Filip Havlík ◽  
Josef Mana ◽  
Petr Dušek ◽  
Robert Jech ◽  
Evžen Růžička ◽  
...  
2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Luiz Felipe Vasconcellos ◽  
João Santos Pereira ◽  
Marcelo Adachi ◽  
Denise Greca ◽  
Manuela Cruz ◽  
...  

Few studies have evaluated magnetic resonance imaging (MRI) visual scales in Parkinson’s disease-Mild Cognitive Impairment (PD-MCI). We selected 79 PD patients and 92 controls (CO) to perform neurologic and neuropsychological evaluation. Brain MRI was performed to evaluate the following scales: Global Cortical Atrophy (GCA), Fazekas, and medial temporal atrophy (MTA). The analysis revealed that both PD groups (amnestic and nonamnestic) showed worse performance on several tests when compared to CO. Memory, executive function, and attention impairment were more severe in amnestic PD-MCI group. Overall analysis of frequency of MRI visual scales by MCI subtype did not reveal any statistically significant result. Statistically significant inverse correlation was observed between GCA scale and Mini-Mental Status Examination (MMSE), Montreal Cognitive Assessment (MoCA), semantic verbal fluency, Stroop test, figure memory test, trail making test (TMT) B, and Rey Auditory Verbal Learning Test (RAVLT). The MTA scale correlated with Stroop test and Fazekas scale with figure memory test, digit span, and Stroop test according to the subgroup evaluated. Visual scales by MRI in MCI should be evaluated by cognitive domain and might be more useful in more severely impaired MCI or dementia patients.


2017 ◽  
Vol 31 (sup1) ◽  
pp. 42-60 ◽  
Author(s):  
Ondrej Bezdicek ◽  
Hana Stepankova ◽  
Bradley N. Axelrod ◽  
Tomas Nikolai ◽  
Zdenek Sulc ◽  
...  

Author(s):  
Jessica Powell ◽  
Lauren Blake ◽  
Kathryn Wyman-Chick ◽  
Michael Daniel

1995 ◽  
Vol 10 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Stephen T. Gancher ◽  
John G. Nutt ◽  
William R. Woodward

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Rie Haga ◽  
Kazuhiro Sugimoto ◽  
Haruo Nishijima ◽  
Yasuo Miki ◽  
Chieko Suzuki ◽  
...  

Background. It is often difficult to differentiate Parkinson’s disease (PD) from multiple system atrophy (MSA), especially in their early stages.Objectives. To examine the clinical utility of histopathological analysis of biopsied skin from the chest wall and/or leg in differentiating between the two diseases.Methods. Skin biopsies from the lower leg and/or anterior chest wall were obtained from 38 patients with idiopathic PD (26 treated with levodopa and 12 levodopa-naïve) and 13 age-matched patients with MSA. We sought aggregates of phosphorylatedα-synuclein on cutaneous nerve fibers using double fluorescence immunohistochemistry and confocal microscopy and measured intraepidermal nerve fiber density (IENFD).Results. Phosphorylatedα-synuclein aggregates were identified on cutaneous nerves in two patients with PD (5.3%) but in none of the patients with MSA, and IENFD was significantly lower in patients with PD when compared to those with MSA. There was no difference in IENFD between levodopa-treated and levodopa-naïve patients with PD.Conclusions. Our findings suggest that an assessment of IENFD in biopsied skin could be a useful means of differentiating between PD and MSA but that detection ofα-synuclein aggregates on cutaneous nerves in the distal sites of the body is insufficiently sensitive.


Sign in / Sign up

Export Citation Format

Share Document